|
End-of-day quote
Buenos Aires S.E.
29/09/2026
|
5-day change | 1st Jan Change | ||
| 19,910.00 ARS | -0.80% |
|
-1.68% | +6.53% |
| 08:50pm | European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading | MT |
| 05:50pm | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 7.44TCr 1,50,56100Cr 9.87TCr 8.69TCr 8.24TCr 14TCr 9,46700Cr 14TCr 99TCr 38TCr 4,84000Cr 37TCr 36TCr 15,51600Cr | P/E 2026 * |
14.4x | P/E 2027 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 9.56TCr 1,93,56500Cr 13TCr 11TCr 11TCr 18TCr 12,17100Cr 18TCr 1,26700Cr 49TCr 6,22200Cr 48TCr 47TCr 19,94800Cr | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
| Markets | Quality | ||
|---|---|---|---|
Buenos Aires S.E.
| GSK | End-of-day quote | |
Buenos Aires S.E.
| GSKD | End-of-day quote |
Last Transcript: GSK plc
| 1 day | -0.80% | ||
| 1 week | -1.68% | ||
| Current month | -0.95% | ||
| 1 month | -2.16% | ||
| 3 months | -2.69% | ||
| 6 months | +0.30% | ||
| Current year | +6.53% |
| 1 week | 19,830 |  | 20,150 |
| 1 month | 19,000 | | 20,510 |
| Current year | 17,020 | | 22,760 |
| 1 year | 15,110 | | 22,760 |
| 3 years | 7,173 | | 22,760 |
| 5 years | 2,171.5 | | 22,760 |
| 10 years | 543.12 | | 22,760 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.80% | -1.68% | - | - | 9.82TCr | |
| -1.18% | +1.36% | +52.90% | +116.74% | 1,05600Cr | |
| -0.51% | -0.99% | +43.73% | +71.77% | 64TCr | |
| -0.06% | -0.75% | +13.62% | +77.46% | 47TCr | |
| -1.83% | -0.90% | +74.85% | +43.10% | 37TCr | |
| -0.06% | -3.88% | +34.32% | +40.74% | 34TCr | |
| -0.79% | +2.01% | +19.82% | +28.48% | 28TCr | |
| -1.19% | -1.21% | +9.82% | +12.15% | 25TCr | |
| -0.22% | +4.24% | +50.00% | +58.95% | 23TCr | |
| -0.79% | -0.76% | +35.33% | +102.73% | 19TCr | |
| Average | -0.69% | +0.12% | +37.15% | +61.34% | 42.4TCr | |
| Weighted average by Cap. | -0.77% | +0.30% | +40.75% | +73.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 68,67000Cr 4.5TCr 3.97TCr 3.76TCr 6.39TCr 4,31800Cr 6.48TCr 45TCr 17TCr 2,20700Cr 17TCr 17TCr 7,07700Cr | 3.55TCr 71,86500Cr 4.71TCr 4.15TCr 3.93TCr 6.69TCr 4,51900Cr 6.78TCr 47TCr 18TCr 2,31000Cr 18TCr 17TCr 7,40600Cr |
| Net income | 519.14Cr 10,51000Cr 689.22Cr 606.92Cr 575.04Cr 978.45Cr 66TCr 991.09Cr 6.88TCr 2.65TCr 34TCr 2.59TCr 2.53TCr 1,08300Cr | 620.94Cr 12,57100Cr 824.37Cr 725.94Cr 687.81Cr 1.17TCr 79TCr 1.19TCr 8.23TCr 3.17TCr 40TCr 3.1TCr 3.03TCr 1,29600Cr |
| Net Debt | 2.12TCr 43,00400Cr 2.82TCr 2.48TCr 2.35TCr 4TCr 2,70400Cr 4.06TCr 28TCr 11TCr 1,38200Cr 11TCr 10TCr 4,43200Cr | 1.85TCr 37,48700Cr 2.46TCr 2.16TCr 2.05TCr 3.49TCr 2,35700Cr 3.54TCr 25TCr 9.44TCr 1,20500Cr 9.23TCr 9.03TCr 3,86300Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | ARS 19,910.00 | -0.80% | 65 |
| 28/26/28 | ARS 20,070.00 | +0.70% | 109 |
| 25/26/25 | ARS 19,930.00 | -0.40% | 37 |
| 24/26/24 | ARS 20,010.00 | +0.30% | 230 |
| 23/26/23 | ARS 19,950.00 | -1.48% | 115 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
